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Prevalence and Measurement of Anxiety
in Samples of Patients With Heart Failure
Meta-analysis
Katherine Easton, PhD, MRes, BSc (Hons); Peter Coventry, PhD, MSc, MA (Econ), BSc;
Karina Lovell, PhD, MSc, BA (Hons), RN; Lesley-Anne Carter, MSc;
Christi Deaton, PhD, RN, FAHA, FESC
Objectives: Rates of anxiety in patients with heart failure (HF) vary widely, and not all assessment instruments
used in this patient population are appropriate. It is timely to consolidate the evidence base and establish the
prevalence and variance of anxiety in HF samples. Methods: A systematic review, meta-analysis, and
meta-regression were conducted to identify the prevalence, variance, and measurement of anxiety in patients
with HF. Results: A total of 14,367 citations were identified, with 73 studies meeting inclusion criteria. A random
effects pooled prevalence of 13.1% (95% confidence interval [CI], 9.25%Y16.86%) for anxiety disorders, 28.79%
(95% CI, 23.30%Y34.29) for probable clinically significant anxiety, and 55.5% (95% CI, 48.08%Y62.83%) for
elevated symptoms of anxiety was identified. Rates of anxiety were highest when measured using the Brief
Symptom Scale-Anxiety scale (72.3%) and lowest when measured using the Generalised Anxiety Disorder-7 (6.3%).
Conclusion: Many patients with HF would benefit if screened for anxiety and treated. The conceptualization
and measurement of anxiety accounted for most variance in prevalence rates. The Generalised Anxiety Disorder-7 or
the Hospital Anxiety and Depression Scale appear to be the most appropriate instruments for this clinical population,
with evidence to suggest they can discriminate between depression and anxiety, omit somatic items that may
contaminate identification of anxiety in a population with physical comorbidities, and provide thresholds with which to
differentiate patients and target treatments. Although there are limitations with the collation of diverse measurement
methods, the current review provides researchers and clinicians with a more granular knowledge of prevalence estimates
of anxiety in a population of HF patients.
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Introduction
More than 30% of individuals with 1 or more physical
long-term conditions may experience comorbid mental
health problems, such as anxiety and depression,1 lead-
ing to increased health complications, consumption of
healthcare, and, in turn, estimated increases in health-
care spending of 45%.2 In the past decade, the interest
in depression in heart failure (HF) research has in-
creased,3Y8 and health professionals are advised to be
aware of and screen for potential depression in patients
with HF.9 Despite evidence to suggest that anxiety often
proceeds depression and that it is as distressing as and
often more prevalent than depression,10Y12 relatively
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little research has been conducted to explore the preva-
lence, nature, and impact of anxiety, particularly in HF.
Recent publications in this area reported rates of anxiety
varying between 8% and 18%13 for anxiety disorders,
17 % and 28.8 % for clinically significant anxiety,14Y16
as well as 40% and 72% for elevated symptoms of
anxiety17Y19 using a variety of measurement instruments
and thresholds to interpret scores from a range of pa-
tient samples and settings.
The accurate measurement and identification of de-
pression and anxiety can be challenging owing, in part,
to the frequent co-occurrence of these conditions (up
to 70% of cases) in clinical and nonclinical samples
alike20 and overlap in symptoms, particularly those of
a physiological nature. Assessing anxiety within the con-
text of a physical disease process can be considered an
even greater challenge because both physical and emo-
tional conditions share many common symptoms includ-
ing fatigue, palpitations, chest pains, breathlessness, and
many more.21 Therefore, measures used to identify anx-
iety must be appropriate for use in this patient popula-
tion. Omitting somatic items in the detection of anxiety
should allow for the separation of the emotional con-
dition from the physical.22
Consolidating the evidence base on the measurement
and prevalence of anxiety in patients with HF is the
first step toward a more comprehensive understanding
of the scale of the problem as well as the development
of interventions to manage anxiety. The only review
conducted to date to establish the prevalence of anx-
iety in HF identified 8 studies to assess the prevalence
of anxiety in patients with HF compared with 33 studies
that reported prevalence of depression23 and prevalence
of anxiety that ranged between 11% and 45%, measured
using 6 different measurement instruments. The review
byYohannesetal23 is not comprehensive, and in addition,
the authors did not report the way in which anxiety
had been conceptualized in the identified articles. It is
unclear whether the rates of anxiety relate to anxiety
symptoms, clinical anxiety, or specific anxiety disorders,
although some of the instruments used to measure anx-
iety in the identified studies assess only anxious mood;
therefore, the rates of anxiety identified in this review
must be interpreted with caution. It is appropriate and
timely to identify, appraise, and summarize the evidence
base in this area.
We report a systematic review and meta-analysis of
research studies that report the prevalence and/or se-
verity of anxiety in samples of patients with HF. The
aims of the systematic review were to identify the pre-
valence of anxiety and methods of measurement in sam-
ples of patients with HF and to identify sources of
variation in reported rates.
Methods
Eligibility Criteria
The eligibility criteria are listed in Table 1.
Search Strategy
The search for relevant articles was conducted by the
author in 3 phases: an initial search of databases (June
2008), an updated search the following year (October
2009), and a final update of the main electronic data-
bases in January 2013. The following databases were
searched from year of inception to January 2013:
h MEDLINE on the OVID platform (1950YJanuary 2013)
h British Nursing Index and Archive on the OVID
platform (1985YOctober 2009) and on Proquest
(January 2013)
h EMBASE on the OVID platform (1980YJanuary 2013)
h PsycINFOusing theOVIDplatform(1806YJanuary2013)
h CINAHL (Cumulative Index to Nursing and Allied
Health Literature) was search initially using the Ovid
platform (1982YJune 2008) and for the updated search
using its current host EBSCOhost (2008Y2013)
h ISI Web of Science with conference proceedings
(1990YJanuary 2013)
h Cochrane Central Register of Controlled Trials using
Wiley Interscience (1980YOctober 2009)
h MetaRegister Current Controlled Trials (mRCT) was
searched, selecting all registers with the exception of
the Leukaemia Research Fund.
h Leading experts in the field were emailed to inquire
about any unpublished work or work in progress.
Index terms, subheading, and free-text terms were
used, along with truncation and combined using Boolean
operators AND and OR. Terms including heart failure,
cardiac failure, and cardiomyopathy were combined
with anxiety, mood disorder, emotional factors, and
specific diagnostic terms including generalised anxiety
disorder. An example of the search strategy is available
in the online appendix, Supplemental Digital Content 1,
http://links.lww.com/JCN/A11. Key articles and reviews
were hand-searched to identify any additional litera-
ture. References were limited in the English language.
Study Selection and Data Extraction
One author (K.E.) screened titles and abstracts against
the inclusion criteria and obtained full-text articles for
assessment. Data from ongoing research, abstracts, and
presentations were obtained from principal investiga-
tors. The review team (P.C., K.L., and C.D.) were con-
sulted to clarify uncertainties of inclusion until a consensus
was reached. Authors were contacted for additional
information when studies contained an HF sample and
valid measure of anxiety but no data, where anxiety
data were not reported separately for HF in a mixed
sample and where demographic and clinical data were
reported for a different number of participants com-
pared with anxiety data. When interventional studies
were included, only baseline data from control and in-
terventional groups were extracted.
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Data extraction was conducted independently by 4
reviewers: K.E. extracted data from all included articles,
whereas the other reviewers (P.C., K.L., and C.D.) each
extracted data from a third of the studies. Extracted
data were compared, and discrepancies in extraction
were discussed with the team until consensus was reached.
A modified extraction form26 was developed, piloted,
and further refined to extract data on the following:
sample size; average age; proportion of males; New York
Heart Association functional class; left ventricular ejec-
tion fraction %; ethnicity; study design, sampling method;
response rate/attrition; geographical location; setting; def-
inition of anxiety; measurement instrument; number
of people with anxiety; average scores on anxiety mea-
surement; and prevalence rate of anxiety.
Quality Assessment
The quality of studies was assessed in 3 stages.
h Firstly, only studies with a validated measure of anx-
iety symptoms were included in the review.
h Secondly, the design of studies was extracted and
used as a variable in the meta-regression analyses to
identify variance in prevalence estimates correlated
to design.
h Finally, a component approach was used to assess
factors considered important for internal validity.27
Bias must be assessed and acknowledged in a system-
atic review so that the results can be considered in light
of this. The selection of participants, measurement of
outcome variables, and appropriate use of analytical
methods to control for confounding variables are key
components that must be considered to assess the in-
ternal validity observational research.28 There is no
standard quality assessment instrument for use with
observational studies or for use in reviews that seek to
document the presence or prevalence of a condition as
opposed to measure the effects of an intervention.29 It
is therefore advised that key components be chosen
relating to an individual review’s context, choice of
design inclusion, and outcome.28 The choice of quality
components was guided by the Strengthening The Re-
porting of Observational Studies in Epidemiology state-
ment,30 evaluating reviews of prevalence31 and in
consultation with the review team.
Further to this, the internal and external validity of
studies was assessed by narratively evaluating the follow-
ing components: evidence of probability sampling, ad-
equate reporting of sampling characteristics, adequate
response rates (80%> acceptable or 70%> if charac-
teristics of nonresponders match responders), concep-
tualization of anxiety, standardized data collection,
appropriateness of anxiety measure instrument; spe-
cifically the omission of somatic items and ability to
TABLE 1 Exclusion and Inclusion Criteria
Inclusion criteria
Population & Acquired left-sided ischemic and nonYischemic HF, confirmed by medical records and/or patients
currently receiving treatment for HF
& Stable inpatients or community-based patients
& Q18 y
& HF as the primary diagnosis
& Patients with HF who received an ICD, CRT, CABG, or PCI will be included if anxiety symptoms/
disorder measurement is not immediate preintervention/postintervention (must be at least 3 mo in
duration after intervention).
Outcome & Validated measure of the severity of anxiety symptoms, clinical anxiety, or anxiety disorders
& Anxiety symptoms are defined as physical and psychological symptoms of generalized anxiety disorder
(DSM-IV 300.02).
& Anxiety disorders are categorized as outlined in DSM-IV.24
Study design & All primary research studies with a quantitative measure of anxiety.
& Randomized controlled trials, uncontrolled trials, and observational research including cohort studies,
case-control trials, and case series as defined by the Royal College of Nursing, Evidence-Based Nursing
levels of evidence guidelines (http://ebp.lib.uic.edu/nursing/?q=node/12)
Exclusion criteria
Population & Heart failure due to congenital heart disease or isolated right-sided HF patient (when specified) or
where there is a diagnosis of pulmonary hypertension or cor pulmonale
& Patients hospitalized with acute, unstable HF
& Concurrent disabling or life-threatening diagnosis being the focus of the study
& Heart transplant or artificial heart pump patients
Outcome & Proxy measures of anxiety that did not assess recognized symptoms of anxiety25; general mental health
measures, dichotomous measures that asked patients if they were anxious.
Study design & Case studies, commentaries, reviews, letters, and other nonprimary research will be excluded.
& Dissertations
& Non English language papers
Abbreviations: ICD, implanted cardioverter defibrillator device; CRT, cardiac resynchronisation therapy; CABG, coronary artery bypass graft; PCI,
percutaneous coronary intervention; DSM, Diagnostic Statistical Manual.
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distinguish between anxiety and depression, as deter-
mined through evaluation of available psychometric
and empirical literature (Table 2). The assessment of
study quality and the appropriateness of measurement
instrument analyses can be found in the online appen-
dix, Tables B and C, respectively, Supplemental Digital
Content 1, http://links.lww.com/JCN/A11.
In quantitative data analysis, the quality components
of sample composition, conceptualization of anxiety,
and appropriateness of measurement instrument were
entered into sensitivity analysis in the meta-regression
to determine whether levels of anxiety varied as a result
of these components. The outcomes of the quality appraisal
were narratively and statistically synthesized with re-
sults from the review.
Data Analysis
Heterogeneity among study outcomes was explored
using the Cochran Q (reported as X2 and P value) and I2
statistic. A significance level ofP < 0.10 was set for the
Q statistic owing to inherent low statistical power in
this test.36 The I2 values of 25%, 50%, and 75% are
indicative of low, moderate, and high levels of hetero-
geneity (variance between studies), respectively. When
heterogeneity was high (>75%), random effects models
were fitted using the command METAN to identify
pooled estimates of the prevalence of anxiety in HF
samples.37
Meta-analysis was performed using Stata 11.0 soft-
ware package.38 Studies that identified specific anxiety
disorders were clustered together (termed anxiety dis-
order). Studies that used measures to screen for levels
of probable anxiety above a given threshold were clus-
tered together (termed probable clinical anxiety). Studies
that used questionnaires to measure anxiety symptoms
that reached levels above the norm for the general popu-
lation were clustered together (termed elevated symptoms
of anxiety). The remaining studies that used measures to
assess symptoms of anxiety with no reference to thresh-
olds with which to identify anxious cases were clustered
together. Not all studies included in the review reported
a prevalence rate of anxiety. Where studies report anxiety
symptom severity (mean, SD, median, interquartile range),
meta-analysis was conducted using measurement in-
strument to determine how levels of anxiety reported
as central tendencies varied as a result of measurement
methods.
Univariate meta-regression analysis was conducted
to explore differences within overall pooled prevalence
estimates39 on the following factors: conceptualization
of anxiety (anxiety disorders, probable clinical anxiety,
and elevated symptoms of anxiety), age (both as a con-
tinuous variable of mean age in years and a categorical
variable of <59 years, 60Y69 years, >70 years), gender
(percentage of males in the sample), setting (inpatient,
outpatient, or mixed), left ventricular ejection fraction
(mean percentage), New York Heart Association (NYHA)
class (mild [>70% of the sample in classes I and II],
moderate/severe [>70% of the sample in classes III and
IV], mixed), design (randomized controlled trial vs un-
controlled trials, cohort, case controlled, case series),
country (United States vs United Kingdom and Europe,
Asia, Australasia, mixed samples, and Africa). In addi-
tion, because conceptualization of anxiety will under-
standably have an impact on reported rates of anxiety,
a planned post hoc analysis was conducted to explore
variations in prevalence rates while controlling for con-
ceptualization of anxiety in a 2-factor meta-regression.
Our study is reported in line with the Preferred Re-
porting Items for Systematic Reviews and Meta-Analyses
statement.27
Results
Identification of Included Studies
Relevant articles were exported in to Reference Man-
ager for management. After reviewing 14,367 articles
and studies, 144 articles met criteria for the review and
72 studies contained sufficient data for inclusion in the
narrative synthesis, of which 38 reported prevalence
data for the meta-analysis and meta-regression (Figure 1,
flowchart of search and screening).
Characteristics of Included Studies
The majority of studies were published between 2009
and 2013, originating mainly in the United States (n = 32),
9 in the United Kingdom, and 16 in Europe. Observa-
tional designs were used most frequently (66%), with
anxiety being a primary outcome over half the included
studies (53%). In total, 26,366 of patients with HF were
sampled: 94% (24, 691) were males, with a mean (SD)
age of 67.5 (11.4) years. The majority of the studies
sampled outpatients (68%). A table of included studies’
characteristics and anxiety data is available in the online
appendix D, Supplemental Digital Content 1, http://
links.lww.com/JCN/A11.
Quality of Included Studies
The assessment of study quality can be seen in Table B,
Supplemental Digital Content 1, http://links.lww.com/
JCN/A11, in the online appendices. The evaluation of
the appropriateness of measurement instrument anal-
yses can be seen in Table 2 and in Table C, Supplemental
Digital Content 1, http://links.lww.com/JCN/A11, in the
online appendices. The characteristics used in the assess-
ment were as follows: evidence of probability sampling,
adequate reporting of sampling characteristics, adequate
response rates (80%> acceptable or 70%> if characteristics
of nonresponders match responders), conceptualization of
4 Journal of Cardiovascular Nursing x Month 2015
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anxiety, standardized data collection, appropriateness
of anxiety measure intrument (specifically the omission
of somatic items and ability to distinguish between anxiety
and depression), as determined through evaluation of
available empirical literature.
The majority of the studies did report sufficient de-
mographic and clinical data (76%), although many did
not report a response rate (74%). Of the 72 studies in
the review, 9 defined or operationalized the construct
of anxiety.16,18,34,40Y45 The choice of instrument to
measure anxiety was a key quality component for the
current review. Fourteen studies used instruments that
were evaluated by the review team as containing so-
matic items; that is, items that assessed physical symp-
toms of anxiety42,46Y54 or could not be considered to
omit somatic items from assessment of anxiety en-
tirely.35,43,55,56 Twenty-five studies used instruments
to evaluate levels of anxiety or identify cases of anxiety
that could not be said to effectively distinguish between
anxiety and depression based on examination of avail-
able empirical literature. In the current review, only the
Hospital Anxiety and Depression Scale (HADs), Brief
Symptom Inventory-Anxiety (BSI-A), Generalised Anx-
iety Disorder 7-item (GAD-7), and the Patient Health
Questionnaire (PHQ) for panic disorder and other anx-
iety disorders were evaluated as demonstrating sound
psychometric evidence for their ability to distinguish
between anxiety and depression. The table of quality
assessment data and the table of anxiety measurement
instruments are available in the online appendix B and C,
Supplemental Digital Content 1, http://links.lww.com/
JCN/A11.
Measurement of Anxiety
Six studies used clinical interviews or questionnaires to
identify specific anxiety disorders including the Struc-
tured Clinical Interview,57,58International Classification
of Diseases, Ninth Revision, Clinical Modification
codes for GAD,59 GAD-7,32 the GAD-2, and the PHQ39
for panic and other anxiety disorders. Forty-five studies
FIGURE 1. Flow diagram to show flow of studies in the review and reasons for exclusions.
6 Journal of Cardiovascular Nursing x Month 2015
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assessed symptoms of anxiety using questionnaires that
facilitate the interpretation of scores as ‘‘normal,’’ ‘‘mild
to moderate,’’ and ‘‘severe/probable clinical anxiety.’’
From these studies, 27 reported a prevalence rate using
a range of recommended threshold to identify caseness
of anxiety. The most commonly used instrument was
HADs22 (n = 28 studies). A range of thresholds were used
to identify anxiety using the HADs, ranging from 11>
to 7>. Nineteen studies measured symptoms of anxiety
using instruments that identify elevated levels of anx-
iety above a general population norm, with 8 of these
studies reporting prevalence rates (Table 3).
Prevalence of Anxiety: Meta-analysis
The prevalence of reported anxiety from 38 studies
ranged from 6.3% to 72.3%, with an overall random
effects pooled prevalence of 32% (95% confidence in-
terval [CI], 26.5%Y37.6%). Substantial heterogeneity
in the rates of reported anxiety was found (x2 = 1745.1,
df = 37, P = .000, I2 = 97.9%; Figure 2). Meta-analysis
identified a random effects pooled prevalence of 13.1%
(95% CI, 9.25%Y16.86%) for anxiety disorders, 28.79%
(95% CI, 23.30%Y34.29%) for probable clinically
significant anxiety and 55.5% (95% CI, 48.08%Y62.83%)
for elevated symptoms of anxiety. Combined prevalence
and mean severity scores by measurement instruments
identified in the review were also calculated (Table 3).
Lower prevalence estimates were identified when studies
used the GAD-7, HADs, and State Trait Anxiety Inven-
tory compared with the BSI-A. Rates of anxiety were
highest when measured by the BSI-A (56.8%; 95% CI,
44.7%Y68.9%) and lowest when measured using an
instrument to identify specific anxiety disorder, the
Hamilton Anxiety Rating Scale (11%). High levels of
heterogeneity were identified in all meta-analysis models
(I2 >0.80).
Variations in Reported Anxiety:
Meta-Regression
In univariate meta-regression analyses, studies in which
anxiety had been conceptualized as specific anxiety dis-
orders identified lower rates of anxiety compared with
studies that measured clinical levels of anxiety symptoms
(" = j14.40 standard error [SE(")] = 5.63, P = 0.015 [)]
and studies that measured symptoms of anxiety, iden-
tifying anxious individuals as those who scored higher
than a general population norm (" = j41.24, standard
error [SE(")] = 6.77, P = .000 [)]. In addition, studies
with a younger mean age (in years) reported higher pre-
valence rates of anxiety (compared with studies with an
older mean age) (" = j1.01, standard error [SE(")] =
0.41, P = .020), and studies with samples that had a
higher proportion of females to males (as opposed to
a higher proportion of males) had higher prevalence
of anxiety (" = j0.62, standard error [SE(")] = 0.21,
P = .006). Studies conducted in the United States re-
ported a higher prevalence of anxiety when compared
with studies conducted in the United Kingdom and
mainland Europe (" = j19.98, SE["] = 5.78, P = .002).
No other factors were found to explain the heterogeneity
in overall prevalence rates to a significant level. A table
of all meta-regression results is available in the online
appendix E, Supplemental Digital Content 1, http://links
.lww.com/JCN/A11.
In post hoc analysis, using a 2-factor meta-regression
when controlling for the variance in rates of anxiety
accounted for by the conceptualization and measure-
ment of anxiety only, age (mean in years), NYHA
functional class, and country of origin explained varia-
tions in anxiety prevalence to a significant degree.
Studies with samples of a lower mean age (" = j0.79,
SE["] = 0.29, P = .009) and higher proportion of indi-
viduals with milder NYHA functional class (" = j15.06,
SE["] = 6.98, P = .041) originating from the United States
TABLE 3 Prevalence Estimates and Anxiety Symptom Severity from Meta-analysis, Grouped by
Anxiety Conceptualiszation and Measurement Instrument
Conceptualization of Anxiety No. Studies Weighted Means, 95% CI No. studies Pooled prevalence %, 95% CI
Anxiety disorders 6 V 6 13.05 (9.25Y16.86)
GAD-7 2 4.26 (2.84Y5.68) 2 14.38 (j2.07 to 30.8)
Probable clinical anxiety 45 V 24 28.79 (23.3Y34.3)
HADS 22 6.16 (5.3 - 7.1) 17 26.54 (19.8Y33.32)
STAI-state 8 36.68 (26.60 Y 46.76) 4 38.8 (29.9Y47.6)
STAI-trait 7 43.14 (35.61Y50.66) 4 36.4 (26.5Y46.3)
Hamilton Anxiety Rating Scale 2 14.07 (13.6Y14.53) 1 11
Geriatric Anxiety Inventory 2 5.016 (4.26Y578) 1 24
Elevated symptoms 19 V 8 32.04 (26.53Y37.56)
BSI-A 13 0.74 (0.68Y0.81) 6 56.8 (44.68Y68.9)
MAACL 5 7.0 (6.2Y7.7) 1 50
Symptoms of anxiety 2 V V V
POMS 3 11.1 (7.7Y14.5) V V
Abbreviations: BSI-A, Brief Symptom Inventory-Anxiety; GAD-7, Generalised Anxiety Disorder 7-item; HADs, Hospital Anxiety and Depression Scale;
MAACL, Multiple Affect Adjective Checklist; POMS, Profile of Mood States; STAI, State-Trait Anxiety Index.
Prevalence of Anxiety in Heart Failure Samples 7
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
(" = j11.20, SE["] = 5.48, P = .050) reported in-
creased prevalence rates of anxiety.
Discussion
This review identified and collates a vast amount of
literature and offers the reader finer granularity regard-
ing the prevalence of anxiety in populations of patient
with HF. There are 3 main findings from the systematic
review. First, random effects pooled prevalence estimate
of anxiety was 32%. The pooled prevalence estimates
of anxiety disorders (13%) are not considered unique to
HF samples and have been observed in older adult com-
munity samples and clinical samples alike.12,60 The pooled
prevalence estimates of probable clinical anxiety symp-
toms (29%) and elevated symptoms of anxiety (56%)
were slightly higher than the rates found in older adult
community samples (15%Y52%),60 in clinical samples
(15%Y56%),60 samples of patients with CAD (20%Y
25%),61 after acute cardiac events (20%Y25%),62 and
after ICD intervention (24%Y87%).63
Second, there was substantial heterogeneity among
study prevalence estimates, indicating that pooled prev-
alence estimates should be interpreted with caution.
Prevalence estimates ranged from 6.3% to 72.3%. In
meta-regression analysis, the way in which anxiety had
been conceptualized and measured in studies was most
strongly associated with heterogeneity. Inflated rates
of anxiety reported in the literature are most likely an
artifact of measurement method.
FIGURE 2. Prevalence of anxiety disorders, probable clinical anxiety, and elevated symptoms of anxiety in samples of
patients with HF grouped by type of anxiety. 0 = specific anxiety disorders group; 1 = probable clinical anxiety group; 2 =
elevated symptoms of anxiety above general population norms group. ES indicates effect size; CI, confidence interval.
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Third, many different measurement instruments were
used to identify anxiety in the included studies, some of
which could be considered to have more clinical utility
and are more appropriate for screening for anxiety in
individuals with a diagnosis of HF than others.
Prevalence Rates
In a critical review of the literature in 2010, Yohannes
et al23 identified only 8 studies that explored anxiety
comorbid to HF, with prevalence estimates from 11%64
to 45%.65 The current review was designed to be more
comprehensive with regard to methods and analysis
and has identified considerably more studies that in-
cluded a measure of anxiety in samples of individuals
with a diagnosis of HF. The review shows that pre-
valence estimates of anxiety range substantially from
6.3% to 72.3%, with lower prevalence estimates found
in studies measuring specific anxiety disorders as op-
posed to elevated levels of anxiety symptoms.
Meta-regression indicated that younger samples
and those with a higher ratio of females to males record
significantly higher levels of anxiety. The finding that
overall anxiety increases as the proportion of females
in a sample increases is consistently supported by re-
search.66 Research examining anxiety in HF samples
and after acute cardiac events identifies female patients
as significantlymoreanxious thanmales.45,46,50,67 Whether
this difference in prevalence rates reflects a behavioral,
social, or physiological propensity toward anxiety in
females is still unclear. Alternatively, or in addition,
higher rates of anxiety identified in females may reflect
a higher frequency in reporting in females compared
with males. An increase in anxiety in younger samples
is not reflected in the literature, with evidence from
general population samples indicating that anxiety in-
creases with age, with up to 17% of elderly men and
21.5% of elderly women experiencing severe anxiety,
although the term elderly is not defined but does sup-
port research conducted with HF samples.68 It is un-
known whether the difference in prevalence rates reflects
a ‘‘real’’ variation in the prevalence of anxiety in younger
and older aged adults or whether anxiety is underdiag-
nosed in elderly patients with HF. Alternatively, the
mental health of elderly patients in general is overlooked
by clinicians.69
The upper range of prevalence estimates found could
indicate that levels of anxiety are higher in samples of
patients with HF compared with many other cardiovas-
cular conditions, with the exception of samples immedi-
ately after invasive procedures. However, the instruments
used to measure anxiety symptoms and thresholds used
to identify caseness of anxiety have played a crucial role
in determining the levels of anxiety identified in the cur-
rent review. Variations in prevalence estimates may not
always reflect true differences in anxiety between dif-
ferent patient populations, but they may be an artifact
of measurement.
Measurement and Relevance for
Clinical Practice
Anxiety was measured using 11 different question-
naires or interviews methods. Scores on questionnaire
measures were interpreted using a variety of differ-
ent threshold to define anxiety, making synthesis of
outcome data difficult, across and within measure-
ment instruments. The quality of measurement instru-
ments varied. Only some have been evaluated by the
review team as appropriate for use in cardiac, elderly
samples and are able to distinguish between anxiety and
depression.
Only 1 study used a criterion standard diagnostic tool
the Structured Clinical Interview for Diagnostic Statis-
tical Manual I57 to diagnose specific anxiety disorders,16
corresponding to United Kingdom’s National Institute
of Care and Health Excellence (NICE) guidelines for
the assessment of generalized anxiety disorder in pri-
mary, secondary, and community care.67 Although this
method of assessing patients is considered robust, it
can take more than an hour to assess patients and in-
volves subjective interpretation of self-reported symp-
toms by a skilled interviewer. This instrument is unlikely
to be appropriate for routine use to screen patients with
HF for mental health complaints in clinical practice
owing to the time taken to complete the assessment and
the training required to conduct the interview. Table 2
presents other measures identified from the review and
highlights key characteristics of interest for clinical prac-
tice. The HADs was the most frequently used measure-
ment instrument in the studies included in the review,
followed by the State Trait Anxiety Inventory and the
BSI-A. The HADs was used mainly in studies from the
United Kingdom and Europe, with the majority of studies
applying a threshold of 8 to identify mild anxiety, which
has been supported through psychometric testing of spec-
ificity and sensitivity.70 The instrument is routinely used
inbothprimaryandsecondarycare in theUnitedKingdom,
which makes the choice of this measure appropriate in
the United Kingdom context; however, issues with the
language used in the measure has reduced its application
in the United States.71 The majority of studies conducted
since the start of 2010 used the HADs to screen for mild,
moderate, and severe levels of anxiety symptoms. Indeed,
many of the studies chose to present the prevalence of
anxiety for more than 1 level of anxiety severity, which
mirrors the use of the HADs in clinical practice and the
ability of the instrument to match patients to ‘‘stepped
care’’ treatment options.
Both the BSI-A72,73 and the Multiple Affect Adjec-
tive Checklist (MAACL)74 were used to measure symp-
toms of anxiety and identify anxious cases with
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reference to data from general population samples. All
of the studies using these measures originated from the
United States, which likely explains the higher rates of
anxiety found by country in the meta-regression. Al-
though it may be suggested that higher rates of anxiety
identified in US studies could reflect differences in care
patterns. The BSI-A and the MAACL are not widely
used in the United Kingdom, where the HADs and
GAD-7 currently meet the needs of assessing anxiety in
an elderly cardiac population. The use of the BSI-A and
MAACL and the interpretation of scores derived from
them based on comparison with general population
norms produced the highest levels of anxiety observed
in the review. Increases in the level of anxiety on the
BSI-A and MAACL are difficult to interpret clinically
because no thresholds have been identified to indicate
mild/moderate or severe levels of anxiety. Because these
instruments identify individuals with elevated symp-
toms of anxiety using low thresholds (general population
norms), it is not surprising that they identify extremely
high prevalence estimates of anxiety. However, the
clinical relevance of identifying such a wide range in
the levels of anxiety is unknown, as is the ability to target
patients at the right treatment using either the BSI-A or
the MAACL.
The GAD-7 offers a solution to the problem of assess-
ing anxiety using criteria of Diagnostic and Statistical
Manual ofMental Disorders, Fourth Edition, in a very
short space of time. The GAD-732 is one of the minimum
data set requirements used by the Increasing Access to
Psychological Treatment (IAPT) program in the United
Kingdom to screen for and identify caseness of anxiety
(mild/moderate).75 Although widely used in the United
Kingdom primary care settings, it was interesting to
note that no studies conducted in the United Kingdom
included in the current review used the instrument.
This is likely to be due to the fact that the IAPT program
is a relatively new national initiative, running in primary
care services. Many of the studies included in the review
would have been conducted before its initiation, and the
majority of research to date has sampled outpatients,
primarily from secondary services. The GAD-7 and its
predecessor, the PHQ, were used in research from the
United States and Germany in the current review. The
instrument is free to use and very brief (7 items). It con-
tains no questions relating to somatic complaints and
can distinguish between anxiety and depression, making
its use in cardiac populations appropriate.32 Scores higher
than 10 have been found to correspond to caseness of
moderate to severe anxiety32 that can impact an
individual’s ability to perform everyday activities and
cause marked distress but responds well to psy-
chological interventions (NICE, 2011; IAPT Toolkit,
2008). The use of the instrument should be encouraged
within the United Kingdom and internationally as large
amounts of data are being routinely collected using this
instrument. In addition, the instrument is open source
and free to use.
Methodological Considerations
Although this review is comprehensive and the first of
its kind, several limitations exist, including the exclu-
sion of non-English language articles and dissertations.
Although studies were excluded from the review if they
did not use a validated measure of anxiety signs and
symptoms, study design was not an exclusion criterion
and the review may contain studies considered to be of
lower quality, which could have an impact on the robust-
ness of reported prevalence rates and precision of esti-
mates. However, the use of observational studies in
systematic reviews and meta-analyses is fairly common
and has increased noticeably in the last 2 decades, par-
ticularly in areas where little randomized controlled
trial or effectiveness research exists.76,77 To increase
precision in prevalence estimates, studies were clustered
according to the manner in which they conceptualized
and measured anxiety, which should go some way to
increasing the precision of estimates. Study design was
included as a variable in meta-regression, but it was
not found to be associated with variance in prevalence
estimates.
For synthesis and appraisal purposes, the manner in
which studies have conceptualized and measured anx-
iety has been subjectively categorized in this review
into the following categories: anxiety disorder (studies
that measured specific anxiety disorders), probable
clinical anxiety (studies that used measures to screen
for levels of probable anxiety above a given threshold),
and elevated symptoms of anxiety (studies that used
questionnaires to measure anxiety symptoms that reached
levels above the norm for the general population). This
clustering of measures was subjective, and the decision
taken was pragmatic to capture a comprehensive range
of data. We have been transparent in regard to this de-
cision and welcome debate. The validity or appropriate-
ness of measurement instruments has been subjectively
evaluated as part of the quality assessment on the basis
of available empirical evidence and in consultation with
the review team. It is hoped that transparency with regard
to the appraisal process of measures should allow deci-
sions to be scrutinized.
The percentage of males in the included studies was
high, which may reflect the inclusion of studies of vet-
erans in the review with predominantly male samples.
Although the findings are representative of the academic
literature, this may reduce the ability to extrapolate from
the data to clinical populations. The findings from the
review should be interpreted with caution in light of this.
Furthermore, high levels of heterogeneity were found
between studies and small numbers of observations
involved in meta-regression analyses. However, when
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using the I2 test, substantial variability exists in the
literature with regard to acceptable upper limits,78 making
it difficult to determine just how much heterogeneity is
acceptable between studies. Further exploration of sources
of heterogeneity in anxiety prevalence estimates and
subgroup analysis within concepts of anxiety was often
not possible owing to the small number of observations
and collinearity of data. No clear consensus exists regard-
ing the lower limit to the number of studies that a meta-
regression should be performed on. Simulations to test
the stability of parameter estimates indicate that fewer
than 10 studies produce unstable estimates, a problem
exacerbated further when sample sizes are small.79 The
reader is advised to interpret findings from meta-regression
with caution. More stringent inclusion criteria may have
improved the issue of variability; however, substantial
heterogeneity existed even within studies grouped by
specific measurement instruments.
Finally, the use of meta-analysis with studies that
contain significant amounts of heterogeneity with re-
spect to outcomes, sample characteristics, and study
design is controversial. However, the use of meta-analysis
and meta-regression is considered justifiable, if not essen-
tial for exploration of stratified prevalence estimates.78
Conclusions
The current review provides researchers and clinicians
with more precise estimates for the prevalence of an-
xiety in populations of patients with HF. The mental
health of patients with a long term condition including
those with HF, is often neglected in clinical practice.78,79
What is evident from the review is that a proportion of
individuals with a diagnosis of HF are experiencing
symptoms of anxiety that may impair their health and
well-being. If identified, these patients may benefit
from clinical interventions. Future research should con-
sider the overlap in symptoms for patients with both
physical and emotional conditions and help to guide ap-
propriate screening of common mental health conditions
in this patient population. Access to psychological services
can be limited and waiting lists long. Therefore, it is im-
portant to target available services to those most in need.
The clinical utility of some measurement instruments
that have been identified in the review has been ques-
tioned. Clinicians must select measurement instruments
with service provisions in mind.
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